ProCE Banner Activity

Audio on Optimizing Switch Strategies for Patients With Viral Suppression

Podcast Episodes
In this on-demand recording of a live webinar, expert faculty discuss important considerations when switching ART in patients with viral suppression on their current regimen, including guideline recommendations and data supporting different switch regimen options such as single-tablet triple therapy, 2-drug oral regimens, doravirine-based regimens, and long-acting injectable therapy.

Released: June 10, 2021

Expiration: June 09, 2022

No longer available for credit.

Share

Faculty

Daniel R. Kuritzkes

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Chloe Orkin

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Faculty of Medicine and Dentistry
Queen Mary University of London
London, United Kingdom

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Faculty of Medicine and Dentistry
Queen Mary University of London
London, United Kingdom